NEW
YORK, Aug. 5, 2022 /PRNewswire/ -- Jakubowitz
Law announces that a securities fraud class action lawsuit has
commenced on behalf of shareholders of TG Therapeutics, Inc.
(NASDAQ: TGTX).
To receive updates on the lawsuit, fill out the
form:
https://claimyourloss.com/securities/tg-therapeutics-inc-loss-submission-form/?id=30567&from=4
The lawsuit seeks to recover losses for shareholders who
purchased TG Therapeutics between January
15, 2020 and May 31, 2022.
Shareholders interested in acting as a lead plaintiff
representing the class of wronged shareholders have until
September 16, 2022 to petition
the court. Your ability to share in any recovery doesn't require
that you serve as a lead plaintiff.
According to a filed complaint, TG Therapeutics, Inc. issued
materially false and/or misleading statements and/or failed to
disclose that: (i) clinical trials revealed significant concerns
related to the benefit-risk ratio and overall survival data of the
Company's therapeutic product candidates, Ublituximab and
Umbralisib; (ii) accordingly, it was unlikely that the Company
would be able to obtain approval from the U.S. Food and Drug
Administration of the Umbralisib marginal zone lymphoma and
follicular lymphoma New Drug Application, the Biologics License
Application for Ublituximab in combination with Umbralisib, the
supplemental New Drug Application for Ublituximab in combination
with Umbralisib, or the Ublituximab relapsing forms of multiple
sclerosis Biologics License Application in their current forms;
(iii) as a result, the Company had significantly overstated
Ublituximab and Umbralisib's clinical and/or commercial prospects;
and (iv) therefore, the Company's public statements were materially
false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities fraud. Attorney
advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/tgtx-shareholder-alert-jakubowitz-law-reminds-tg-therapeutics-shareholders-of-a-lead-plaintiff-deadline-of-september-16-2022-301600837.html
SOURCE Jakubowitz Law